• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PLoS Biol . Variant mutation G215C in SARS-CoV-2 nucleocapsid enhances viral infection via altered genomic encapsidation

tetano

Editor, Senior Moderator
PLoS Biol


. 2025 Apr 29;23(4):e3003115.
doi: 10.1371/journal.pbio.3003115. eCollection 2025 Apr. Variant mutation G215C in SARS-CoV-2 nucleocapsid enhances viral infection via altered genomic encapsidation

Hannah C Kubinski[SUP] 1 [/SUP], Hannah W Despres[SUP] 1 [/SUP], Bryan A Johnson[SUP] 2 3 4 [/SUP], Madaline M Schmidt[SUP] 1 [/SUP], Sara A Jaffrani[SUP] 1 [/SUP], Allyson H Turner[SUP] 1 [/SUP], Conor D Fanuele[SUP] 1 [/SUP], Margaret G Mills[SUP] 5 [/SUP], Kumari G Lokugamage[SUP] 2 [/SUP], Caroline M Dumas[SUP] 6 [/SUP], David J Shirley[SUP] 7 [/SUP], Leah K Estes[SUP] 2 [/SUP], Andrew Pekosz[SUP] 8 [/SUP], Jessica W Crothers[SUP] 9 [/SUP], Pavitra Roychoudhury[SUP] 5 [/SUP], Alexander L Greninger[SUP] 5 10 [/SUP], Keith R Jerome[SUP] 5 10 [/SUP], Bruno Martorelli Di Genova[SUP] 1 [/SUP], David H Walker[SUP] 2 3 4 11 [/SUP], Bryan A Ballif[SUP] 6 [/SUP], Mark S Ladinsky[SUP] 12 [/SUP], Pamela J Bjorkman[SUP] 12 [/SUP], Vineet D Menachery[SUP] 2 13 14 15 [/SUP], Emily A Bruce[SUP] 1 [/SUP]



Affiliations
Abstract

The evolution of SARS-CoV-2 variants and their respective phenotypes represents an important set of tools to understand basic coronavirus biology as well as the public health implications of individual mutations in variants of concern. While mutations outside of spike are not well studied, the entire viral genome is undergoing evolutionary selection, with several variants containing mutations in the central disordered linker region of the nucleocapsid (N) protein. Here, we identify a mutation (G215C), characteristic of the Delta variant, that introduces a novel cysteine into this linker domain, which results in the formation of a more stable N-N dimer. Using reverse genetics, we determined that this cysteine residue is necessary and sufficient for stable dimer formation in a WA1 SARS-CoV-2 background, where it results in significantly increased viral growth both in vitro and in vivo. Mechanistically, we show that the N:G215C mutant has more encapsidation as measured by increased RNA binding to N, N incorporation into virions, and electron microscopy showing that individual virions are larger, with elongated morphologies.


 
Back
Top Bottom